After falling short in a confirmatory clinical trial, Gilead Sciences has decided to withdraw Trodelvy as a bladder cancer treatment in the U.S. The California biotech announced the decision ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Gilead Sciences has issued a voluntary recall of one lot of COVID-19 antiviral Veklury, also known as remdesivir, after confirming "the presence of a glass particle" in a vial. A customer ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

(RTTNews) - Foster City, California-based Gilead Sciences, Inc. is recalling one lot of Veklury (remdesivir) for Injection 100 mg/vial for treating COVID-19, to the consumer level, due to the ...

In the latest market close, Gilead Sciences (GILD) reached $85.21, with a +0.92% movement compared to the previous day. The stock's performance was behind the S&P 500's daily gain of 0.97%.

In response to increased criticism of its pricing, Gilead Sciences has reached voluntary licensing deals with companies to make generic versions of its twice-yearly HIV medicine, lenacapavir ...

View Gilead Sciences, Inc. (GILD) current and estimated P/E ratio data provided by Seeking Alpha.

**NM signifies a non meaningful value. A dash signifies the data is not available.